Article
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
Clinical pharmacology and therapeutics - 1 Nov 2010
Goh B C, Reddy N J, Dandamudi U B, Laubscher K H, Peckham T, Hodge J P, Suttle A B, Arumugham T, Xu Y, Xu C-F, Lager J, Dar M M, Lewis L D
Abstract excerpt
Pazopanib, an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases, inhibits multiple cytochrome P450 (CYP450) enzymes in vitro. This study in patients with advanced cancer evaluated the effect of pazopanib on CYP450 function by comparing the pharmacokinetics of CYP-specific probe drugs in the presence and absence of pazopanib. The probes used...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.